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Edited by Robert BaroukiAbstract A novel gene named fad104 (factor for adipocyte
diﬀerentiation-104), whose expression level quickly increased in
the early stage of adipogenesis, was isolated and characterized.
The deduced amino acid sequence of fad104 revealed the possible
presence of a ﬁbronectin type III domain and transmembrane
domain. The expression of fad104 was detected in adipocyte
diﬀerentiable 3T3-L1 cells but not observed in the non-adipo-
genic cell line NIH-3T3. Moreover, the ability of 3T3-L1 cells to
diﬀerentiate declined with the knockdown of fad104 by RNA
interference, strongly indicating that fad104 functions as a
positive regulator of adipogenesis.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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The key role of white adipose tissue is the storage of energy
in the form of triglycerides. Adipose tissue provides adipocy-
tokines for maintenance of the balance between energy intake
and energy output [1]. Since the functions of these adipocy-
tokines are disrupted in obese individuals, obesity is associated
with a number of important diseases [2]. Adipocyte growth
occurs with an increase in the size and number of adipocytes
derived from the diﬀerentiation of precursor cells. Several lines
of evidence revealed that peroxisome proliferator-activated
receptor c (PPARc), some of the CCAAT/enhancer-binding
protein (C/EBP) family and sterol regulatory element binding
protein-1 (SREBP-1) function as master regulators of adipo-
cyte diﬀerentiation.* Corresponding author. Fax: +81-52-836-3455.
E-mail address: imagawa@phar.nagoya-cu.ac.jp (M. Imagawa).
Abbreviations: fad, factor for adipocyte diﬀerentiation; C/EBP,
CCAAT/enhancer-binding protein; Dex, dexamethasone; DMEM,
Dulbecco’s modiﬁed Eagle’s medium; FBS, fetal bovine serum; IBMX,
3-isobutyl-1-methylxantine; ORF, open reading frame; PPARc, per-
oxisome proliferator-activated receptor c; RACE, rapid ampliﬁcation
of cDNA ends; RGS2, regulator of G protein signaling 2; RT-PCR,
reverse transcriptase coupled-PCR; shRNA, short-hairpin RNA;
SREBP, sterol regulatory element-binding protein; TCL/TC10bL,
TC10-like/TC10bLong
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doi:10.1016/j.febslet.2004.09.062The ectopic expression of PPARc directs cells to become
adipogenic [3]. C/EBPa was also identiﬁed as a master regu-
lator in an ectopic expression experiment [4]. The positive
feedback activity of C/EBPa against PPARc is also important
for the maintenance of the adipogenic state [5]. C/EBPb and C/
EBPd are known to induce the expression of C/EBPa and
PPARc [6]. C/EBPb was shown to participate in mitotic clonal
expansion by loss of function experiments [7]. Until now, ad-
ipogenesis has been explained by a complex series of transac-
tivations of target genes by these master regulators. However,
it is impossible to elucidate the mechanism of adipogenesis
based only on these factors. Moreover, their expression is
observed from the mid phase to log phase of adipogenesis and
the factors initiating diﬀerentiation at the earliest phase are
poorly isolated and characterized.
Adipocyte diﬀerentiation is imitated by 3T3-L1 preadipo-
cytes in vitro, in response to adipogenic inducers. In our lab-
oratory, using this cell line, factors which were expressed 3 h
after the stimulation were isolated. Of the 102 genes isolated
[8,9], there included regulator of G protein signaling 2 (RGS2)
[10], TC10-like/TC10bLong (TCL/TC10bL) [11], BACH1,
ARA70 [9] and p68 RNA helicase [12]. Further investigation
was done with RGS2, TCL/TC10bL and p68 RNA helicase,
which have now been characterized as factors accelerating
adipocyte diﬀerentiation [10–12].
In this study, we report the cloning and functional analysis
of the gene fad104 (factor for adipocyte diﬀerentiation-104).
Fad104 contains a ﬁbronectin type III domain and trans-
membrane domain. Its expression was elevated during the
adipogenesis of mouse 3T3-L1 cells. The expression of fad104
was strongly restricted to the adipocyte diﬀerentiable 3T3-L1
cells and was not detected in the non-adipogenic cell line, NIH-
3T3. Moreover, when fad104 expression was knocked down
using the RNA interference (RNAi) method, the ability of
3T3-L1 cells to diﬀerentiate declined. Taken together, these
results strongly indicate that fad104 is another factor which
possesses a signiﬁcant role in adipocyte diﬀerentiation.2. Materials and methods
2.1. RNA isolation and northern blot analyses
Total RNA was extracted with TRIzol (Gibco-BRL life Technolo-
gies, Inc., Grand Island, NY) according to the manufacturer’s in-
structions. For Northern blot analyses, 15–25 lg of total RNA wasblished by Elsevier B.V. All rights reserved.
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then transferred to a Hybond-N+ nylon membrane (Amersham Bio-
sciences). Each probe was labeled with [a-32P]dCTP using a BcaBEST
labeling kit (Takara Biomedicals, Kusatsu, Japan).
2.2. Cloning of full-length cDNA of mouse fad104
Since mouse fad104 cDNA was isolated as a small 584 bp fragment,
library screening, the 50-rapid ampliﬁcation of cDNA ends (50-RACE)
and the reverse transcriptase coupled-polymerase chain reaction (RT-
PCR) were used for the cloning of full-length cDNA. Library screening
was done using the mouse kidney kgt10 cDNA library (BD Biosciences
CLONTECH). 50-RACE was performed using a Marathon cDNA
Ampliﬁcation Kit (BD Biosciences CLONTECH) following the in-
structions of the manufacturer. Total RNA was prepared from 3T3-L1
cells 3 h after induction. mRNA was isolated from total RNA using
oligotex-dT30 (Daiichi Pure Chemicals, Tokyo, Japan) according to
the manufacturer’s directions.
The single strand cDNA was ampliﬁed with oligo(dT) primer and
AMV reverse transcriptase. The second strand cDNA was synthesized
using a second-strand enzyme cocktail containing RNase H, Esche-
richia coli DNA polymerase I, and E. coli DNA ligase. The resultant
double stranded cDNA was ligated to a Marathon cDNA adapter by
T4 DNA ligase. The PCR was performed using the forward primer
AP-1: 50-CCATCCTAATACGACTCACTATAGGGC-30 and a
fad104-speciﬁc reverse primer-1: 50-GCTTGCCCGCCGCTTCCTT-
CTCTTC-30, and primer-2: 50-GGTGCGCAGCTATGGGTGGT-
GAAGC-30. The fragments obtained from 50-RACE were subcloned
into a T-added EcoRV site of pBluescript KS+.
2.3. DNA sequencing and database analysis
The sequence was determined with the automated sequencer DSQ-
1000 (Shimadzu Corp., Kyoto, Japan) and an ABI PRISM 310 (Ap-
plied Biosystems, Foster City, CA). The human ortholog of fad104 was
predicted using the Human Genome Database. Searches for the human
ortholog in the Human Genome Database were performed using
BLAST programs accessed via the NCBI homepage.
2.4. Cell culture and diﬀerentiation
Mouse 3T3-L1 (ATCC CL173) preadipocyte cells were maintained
in Dulbecco’s modiﬁed Eagle’s medium (DMEM) containing 10% calf
serum. For the diﬀerentiation experiment, the medium was replaced
with DMEM containing 10% fetal bovine serum (FBS), 10 lg/ml of
insulin, 0.5 mM 3-isobutyl-1-methylxanthine (IBMX) and 1 lM
dexamethasone (Dex) at 2 days post-conﬂuence. After 2 days, the
medium was changed to DMEM containing 5 lg/ml of insulin and
10% FBS, then the cells were refed every 2 days. Mouse 3T3-F442A
(ECACC 70654) cells were maintained in DMEM containing 10% calf
serum. For the diﬀerentiation experiment, the medium was replaced
with DMEM containing 10% FBS and 5 lg/ml of insulin at conﬂuent.
The cells were refed every 2 days. Mouse NIH-3T3 (clone 5611, JCRB
0615) ﬁbroblastic cells were maintained in DMEM containing 10% calf
serum.
2.5. Fractionation of fat cells
The fat cells were prepared as described previously [13]. In brief,
epidermal fat pads were isolated from male C57Bl/6J mice aged 6
weeks, washed with sterile PBS, minced, and washed with Krebs–
Ringer bicarbonate (KRB) buﬀer (pH 7.4). Then, the minced tissue
was digested with 1.5 mg/ml of collagenase type II (Sigma–Aldrich,
Inc., St. Louis, MO) in KRB buﬀer, containing 4% bovine serum al-
bumin at 37 C for 1 h on a shaking platform. The undigested tissue
was removed with a 250 lm nylon mesh and the digested fraction was
centrifuged at 500 g for 5 min. The adipocytes were obtained from
the most upper layer, washed with buﬀer, and centrifuged to remove
other cells. The stromal-vascular cells were resuspended in the eryth-
rocyte lysis buﬀer (150 mM NH4Cl, 25 mM NH4HCO3 and 1 mM
EDTA (pH 7.7)), ﬁltered through 28 lm nylon mesh and then pre-
cipitated at 500 g for 5 min.
2.6. RNAi experiment
The ﬁve target regions (1: 160–178 bp; 2: 627–645 bp; 3: 1078–1096
bp; 4: 1813–1831 bp; and 5: 3391–4009 bp) were selected using the
QIAGEN siRNA online design tool (http://sirna.qiagen.com/) for the
RNAi experiment with fad104. A 19-nt short-hairpin RNA (shRNA)-
coding fragment with a 50-TTCAAGAGA-30 loop was subcloned intothe ApaI/EcoRI site of pSilencer 1.0-U6 (Ambion, Inc., Austin, TX).
As a negative control, the scrambled fragment 50-GTAAGATGA-
GGCAATGGAG-30 which does not have similarity with any mRNA
listed in GenBank was generated.
Transfection of shRNA-expressing vectors into 3T3-L1 cells was
performed with Nucleofector (Amaxa, Cologne, Germany) using Cell
Line Nucleofector Kit V (Amaxa). 3T3-L1 cells were harvested and
resuspended in Nucleofector solution at 1.0 106 cells/100 ll. After
addition of 9 lg of shRNA expression vectors, the cells were trans-
fected using program ‘T-20’ of Nucleofector. Then, the cells were
spread on 6- or 24-well plates. The transfected 3T3-L1 cells were
subjected to diﬀerentiation experiments three days after the transfec-
tion. The diﬀerentiation experiments were done using the same in-
duction medium described above.
2.7. Real-time quantitative RT-PCR (Q-PCR)
Isolation and reverse transcription of total RNA were done as
described above. ABI PRISM 5700 sequence detection system (Ap-
plied Biosystems) was used to perform Q-PCR. The pre-designed
primers and probe sets of fad104, PPARc, C/EBPa, C/EBPb, C/
EBPd, SREBP-1, LPL and 18S rRNA were obtained from Applied
Biosystems. The reaction mixture was prepared using a TaqMan
Universal PCR Master Mix (Applied Biosystems) according to the
manufacturer’s instructions. The mixture was incubated at 50 C for
2 min and at 95 C for 10 min, and then the PCR was done at 95 C
for 15 s and at 60 C for 1 min for 40 cycles. The relative standard
curves were generated in each experiment to calculate the input
amounts of the unknown samples.3. Results
3.1. Expression of fad104 during the early stages of
adipogenesis
We previously reported the isolation of 102 clones, which
were expressed at 3 h after induction by the PCR-subtraction
cloning method. Since BLAST searches revealed no signiﬁcant
matches against proteins of known function, 46 clones are
thought to be novel genes [8,9]. To investigate the role of one
of these genes, fad104, during adipocyte diﬀerentiation, we ﬁrst
determined the time course of fad104 expression during the
early stages of adipogenesis of mouse 3T3-L1 cells by North-
ern blotting (Fig. 1A). While the expression of fad104 was
almost undetectable before stimulation, it was quickly upreg-
ulated after the induction, and reached a peak at 3 h and then
declined until 24 h after the induction. For exact quantiﬁcation
of the signal for fad104 mRNA, we performed Q-PCR for
fad104 during the early and late stages of adipogenesis of 3T3-
L1 cells (Fig. 1B). The expression level of fad104 in 3T3-L1
cells reached a peak at 3 h after induction. We also determined
the expression level of fad104 in mouse 3T3-F442A cells, which
are another preadipocytes and do not require IBMX and Dex
for diﬀerentiation (Fig. 1C). Interestingly, fad104 expression
reached a peak at 3 h as found in 3T3-L1 cells. These ﬁndings
indicate that fad104 expresses transiently at the early stages of
adipocyte diﬀerentiation.
3.2. Expression proﬁle of fad104 in the adipocyte diﬀerentiable
state and the non-diﬀerentiable state
Since the expression of fad104 was observed in the earliest
stage of adipogenesis, we next compared the expression level of
fad104 between the adipocyte diﬀerentiable state and non-
diﬀerentiable state. It is well documented that 3T3-L1 cells
undergo diﬀerentiation when stimulated at 2 days post-
conﬂuence (growth arrested), while proliferating 3T3-L1 cells
do not diﬀerentiate in response to adipogenic inducers. Another
mouse ﬁbroblast cell line, NIH-3T3, is non-adipogenic and
Fig. 2. Expression proﬁle of fad104 in the adipocyte diﬀerentiating and
non-diﬀerentiating cells. Total RNA was isolated from proliferating
and post-conﬂuent 3T3-L1 and NIH-3T3 cells, before and 3 h after
induction. A 25 lg amount of isolated total RNA is loaded in each
column. Relative intensity is also shown.
Fig. 3. Cloning of mouse fad104 and the deduced amino acid structure
of mouse and human FAD104. (A) The full-length cDNA for mouse
fad104 was isolated by 50-RACE and library screening. Su, R-50-1, R-
50-2, and L indicate the fragments obtained from the original sub-
traction, 50-RACE, and library screening, respectively. The combined
sequence is shown as fad104 and start and stop codons are indicated.
The predicted number of amino acids for mouse FAD104 is 1207.
(B) The schematic representation of mouse and human FAD104. The
deduced amino acid sequences encoded by the 3621 bp ORF of mouse
fad104 and 3612 bp ORF of human fad104. The nine repeats of the
ﬁbronectin type III domain (according to NCBI RPS-BLAST) and
single transmembrane domain (according to the SOSUI system) are
shown.
Fig. 1. Time course of fad104 mRNA expression in the early stages of
adipocyte diﬀerentiation. (A) Northern blot analysis of fad104 ex-
pression in 3T3-L1 cells. Total RNA from diﬀerent time points after
the induction was prepared from 3T3-L1 cells. Isolated total RNA (15
lg) was loaded and subjected to Northern blot analysis of fad104. b-
Actin as a control is also shown. (B) Q-PCR analysis of fad104 ex-
pression in 3T3-L1 cells. The expression level of fad104 was determined
at various time points of adipocyte diﬀerentiation of 3T3-L1 cells by
Q-PCR and normalized with 18S rRNA expression determined by Q-
PCR. Each column represents the mean with standard deviation
(n ¼ 3). (C) Q-PCR analysis of fad104 expression in 3T3-F442A cells.
The expression level of fad104 was determined at various time points of
adipocyte diﬀerentiation of 3T3-F442A cells by Q-PCR and normal-
ized with 18S rRNA expression determined by Q-PCR. Each column
represents the mean with standard deviation (n ¼ 3).
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or proliferating state. These two cell lines were stimulated
with inducers for 3 h. Total RNA was prepared from non-
stimulated cells (0 h) and from cells at 3 h after stimulation.
Expression of fad104 was only elevated in the growth-arrested
3T3-L1 cells, its expression was not observed in the other three
states (Fig. 2). These results indicate that the expression of
fad104 is strongly restricted to the adipocyte diﬀerentiable
state.
3.3. Cloning of full-length mouse fad104 cDNA
To prevent bias, ampliﬁed cDNA fragments isolated by the
PCR-subtraction cloning method were digested into 300–500
bp fragments by RsaI [8]. Consequently, the fad104 cDNA
fragment obtained by this cloning method was 584 bp long.Therefore, we next isolated the full-length cDNA of fad104
using library screening and 50-RACE as shown in Fig. 3A.
Mouse kidney library screening using the subtracted fad104
fragment as a probe enabled us to isolate a 1606 bp fragment
Fig. 4. Genomic structure of mouse fad104 obtained from the Mouse
Genome Database. (A) The exon–intron structure of mouse fad104
predicted from the Mouse Genome Database. (B) The nucleotide se-
quences at the exon–intron junctions of mouse fad104. The sequences
in uppercase and lowercase letters are those of exons and introns, re-
spectively. The GT/AG nucleotides at the beginning and end of the
introns are shown in boldface.
Fig. 5. Tissue distribution of fad104. The expression level of fad104 in
various tissues isolated from C57Bl/6J mice was determined by Q-PCR
and normalized with 18S rRNA expression determined by Q-PCR.
Stromal-vascular cells and adipocytes were fractionated from isolated
white adipose tissue. Each column represents the mean with standard
deviation (n ¼ 3). WAT, white adipose tissue; BAT, brown adipose
tissue.
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identiﬁed a mouse EST that shows 100% similarity with fad104
and contains a poly A additional signal at the 30 terminal.
We next performed 50-RACE using cDNA prepared from
3T3-L1 cells 3 h after induction and isolated a 3215 bp cDNA
fragment with the ﬁrst 50-RACE (R-50-1 in Fig. 3A). In the
second 50-RACE, a 1205 bp cDNA fragment including a 712
bp unidentiﬁed region was obtained (R-50-2 in Fig. 3A). Fi-
nally, the combined sequences of the subtracted fragment and
fragments obtained by the 50-RACE, library screening, and
database search resulted in a full-length 6812 bp cDNA frag-
ment with an open reading frame (ORF) of 1207 amino acids
(GenBank Accession No. AB098596).
3.4. Sequence analyses of mouse and human fad104
We attempted to predict the human ortholog cDNA of
fad104 by making a BLAST search of the Human Genome
Database [14] using the mouse fad104 sequence. The search
indicated a genomic fragment located at locus 3q26+ 3 of
human chromosome 3 and comprising 25 exons and 24 in-
trons. In all the exon/intron junctions, the GT/AG rule was
conserved (data not shown). By splicing out the introns and
combining the exons, the human ortholog of fad104 was pre-
dicted. The human ortholog of fad104 was a 6894 bp cDNA
containing a 3612 bp ORF encoding 1204 amino acids (Gen-
Bank Accession No. AB098597). In both mouse and human
fad104, an ATG at position 61, existing at the 50-end within the
coding region of the cDNA, is likely to serve as the start codon
for translation initiation, although the sequence ﬂanking this
ATG does not conform very well to Kozak’s rule [15].
A BLAST search of the Conserved Domain Database using
the deduced amino acid sequences of mouse and human
FAD104 revealed the existence of 9 repeats of the ﬁbronectin
type III domain. A search with the SOSUI system showed that
a single transmembrane domain was present in the C-terminal
end of the mouse and human FAD104 (Fig. 3B).
3.5. Genomic distribution of mouse fad104
The genomic distribution of fad104 was identiﬁed by a
BLAST search of The Mouse Genome Database, which was
made public by The Mouse Genome Sequencing Consortium
[16]. The search indicated that mouse fad104 was located at
3A3 of mouse chromosome 3 and constituted 26 exons and 25
introns. In the sequences of the exon/intron junctions, the GT/
AG rule was conserved in all cases (Fig. 4).
3.6. Expression of fad104 in various mouse tissues
To examine the tissue distribution of fad104, Q-PCR was
performed for fad104 against brain, heart, skeletal muscle,
kidney, lung, liver, testis, white adipose tissue (WAT) and in-
terscapular brown adipose tissue (BAT) isolated from adult
mouse. WAT was fractionated into stromal-vascular cells and
adipocytes. Interestingly, the expression of fad104 was found
to be highly WAT selective and the level of expression in other
organs including BAT was relatively low. Moreover, its ex-
pression was higher in the stromal-vascular cells, indicating
that the expression of fad104 is predominant in preadipocytes
(Fig. 5).
3.7. RNAi experiment on fad104 in 3T3-L1 cells
As described above, the transient expression of mouse
fad104 was observed at an early stage in the diﬀerentiation of3T3-L1 cells. Furthermore, its expression was strongly re-
stricted to cells in a diﬀerentiable state. However, the function
of fad104 in adipocyte diﬀerentiation remains unknown. For
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conducted an RNAi experiment to knock down the expression
of fad104 in adipogenesis. Five shRNA expression vectors with
diﬀerent target regions were introduced into 3T3-L1 cells.
Three days after the transfection, cells were stimulated with
adipogenic inducers. Three hours after the induction, total
RNA was isolated and expression levels of fad104 were iden-
tiﬁed by RT-PCR. Of the ﬁve target regions, region 4 showed
the greatest reduction in activity (data not shown). Therefore,
we used the region 4-shRNA expression vector for further
analyses.
First, we performed RT-PCR to detect fad104 mRNA and
found that the expression was knocked down. However, since
RT-PCR is semi-quantitative, we next conﬁrmed the expres-
sion level of fad104 by Northern blot analysis. As shown in
Fig. 6A, fad104 expression in shRNA expression vector-
transfected cells had declined compared with that in the con-Fig. 6. The functional analysis of fad104 by RNAi. (A) The endoge-
nous expression of the fad104 gene was determined by Northern blot
analysis. Total RNA (15 lg) obtained from 3T3-L1 cells transfected
with shRNA expression vector for fad104 (sifad104) or with scrambled
shRNA expression vector as a control (Control) was subjected to
Northern blot analysis of fad104. Staining with ethidium bromide
(EtBr) for ribosomal RNA is shown as a control. (B) Diﬀerentiation of
3T3-L1 cells transfected with shRNA expression vector for fad104
(sifad104) or with scrambled shRNA expression vector as a control
(Control) was stimulated with inducers. After 8 days, the cells were
ﬁxed and stained with Oil red O to detect oil droplets. Bar, 200 lm.
Staining was done on 6-well plates. (C) The amounts of triacylglycerol
were measured. The measurement of triacylglycerol content was done
on 24-well plates. The column shows the mean with standard deviation
(n ¼ 3). (D) Eﬀect of shRNA expression for fad104 on the expression
of various adipogenic genes. Total RNA obtained from sifad104 cells
(white bar) or Control (gray bar) at each time point was subjected to
Q-PCR. Expression level was normalized with 18S rRNA expression
determined by Q-PCR. Each column represents the mean with stan-
dard deviation (n ¼ 3).trol cells. Using these transfected cells, we conducted a diﬀer-
entiation experiment. Three days after the transfection, the
cells were treated with inducers. After 8 days of induction,
the cells were ﬁxed and stained with Oil red O (Fig. 6B) and the
amounts of triacylglycerol were determined (Fig. 6C). The
number of Oil red O-stained cells was decreased in the shRNA
expression vector-transfected cells and the accumulation of
triacylglycerol was also reduced. These results imply that the
decrease in fad104 expression reduces the ability of 3T3-L1
cells to diﬀerentiate.
Next, we determined the expression proﬁles of adipogenic
marker genes by Q-PCR (Fig. 6D). During the diﬀerentiation
of sifad104 cells, the expression levels of PPARc, C/EBPa,
SREBP-1 and LPL were declined when compared with those
in the control cells. These results strongly indicate that the
reduction of fad104 expression inhibits the adipogenesis of
3T3-L1 cells. Interestingly, the expression levels of C/EBPb
and C/EBPd were unchanged.4. Discussion
The PPARc and C/EBP families have been implicated in
adipocyte diﬀerentiation as master regulators. PPARc and C/
EBPa were demonstrated to have critical roles during adipo-
cyte diﬀerentiation in a gain of function experiment [3,4]. The
knocking out of PPARc resulted in mice that failed to develop
adipocytes [17]. The same result was also obtained on the
knocking out of C/EBPa [18]. The expression of C/EBPb and
C/EBPd is observed earlier than that of PPARc and C/EBPa
[19]. It is shown that coexpression of C/EBPb and C/EBPd
contributes to the expression of PPARc and C/EBPa [6,20].
Double knockout of C/EBPb and C/EBPd disrupted the for-
mation of adipose tissue in mice. However, PPARc and C/
EBPa were normally expressed [21]. Moreover, the genes ex-
pressed prior to C/EBPb and C/EBPd during adipocyte dif-
ferentiation remain largely unknown. These results indicate
that an unknown cascade underlies adipogenesis, especially in
the early stages.
In our laboratory, we have been focusing on the earliest
steps of diﬀerentiation, since the initiation of adipogenesis is
poorly understood as described above. We have already
identiﬁed RGS2, TCL/TC10bL and p68 RNA helicase as
factors accelerating adipogenesis which are expressed at the
very beginning of diﬀerentiation [10–12]. In the present study,
we have cloned and characterized fad104. Fad104 was one of
the 46 unknown genes included in the cDNA pool of 102 genes
isolated by the PCR-subtraction cloning method [8,9]. Ex-
pression of fad104 was observed 3 h after the stimulation of
mouse 3T3-L1 cells and 3T3-F442A cells with adipogenic in-
ducers. Mouse 3T3-L1 cells do not diﬀerentiate into adipocytes
when kept in a proliferating state. Mouse NIH-3T3 ﬁbroblasts
do not diﬀerentiate into adipocytes either even in a growth-
arrested state. Since the expression of fad104 was only ob-
served in growth-arrested 3T3-L1 cells, it was restricted to the
adipocyte diﬀerentiable cells.
Owing to the interesting expression pattern of fad104 during
adipogenesis, we attempt to isolate full-length cDNA of
fad104. Fad104 was characterized as a 6812 bp cDNA with an
ORF of 3621 bp encoding 1207 amino acids. Prediction of the
fad104 human homolog was done by searching the Human
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bp long containing a 3612 bp ORF of 1204 amino acids. The
human ortholog of FAD104 was three amino acids shorter
than its mouse counterpart. Interestingly, the mouse and hu-
man amino acid sequences were highly conserved with 92.5%
similarity. A BLAST search of the Conserved Domain Data-
base and the SOSUI system indicated that FAD104 has nine
ﬁbronectin type III domains and a single transmembrane do-
main in both mouse and human.
Using another transmembrane prediction system
‘TMHMM’, FAD104 is found to have only three amino acids
in inner membrane region. Preadipocyte factor 1 (pref-1) has a
single transmembrane like FAD104 and functions as a nega-
tive regulator of adipocyte diﬀerentiation. Interestingly, it is
reported that this protein is processed at the membrane-
proximal processing site and functions as a soluble protein
[22]. Therefore, we have searched for the same cleavage site in
FAD104 and checked the possibility of FAD104 as a soluble
protein by proteolytic maturation. However, the cleavage site
of pref-1 was not conserved in FAD104. A possible link be-
tween the preadipocytes and the extracellular matrix to regu-
late adipose conversion remains to be elucidated. The eighth
ﬁbronectin repeat of mouse fad104 contained an arginine–
glycine–aspartic acid (RGD) tripeptide sequence, which is a
potential cell-binding domain via integrin [23]. The ﬁbronectin
type III domain is found in proteins like cell adhesion mole-
cules and cell surface receptors.
The tissue distribution analysis revealed that fad104 was
predominantly expressed in WAT, especially, highly expressed
in the stromal-vascular cells than in adipocytes. Therefore, we
next performed a functional analysis of fad104 using the RNAi
method. When the expression of fad104 was downregulated
during the initiation of adipogenesis of 3T3-L1 cells, the ac-
cumulation of oil was suppressed, indicating that fad104 has
an important role in adipogenesis. Furthermore, the expres-
sion levels of PPARc, C/EBPa and SREBP-1 as well as LPL
were declined, while those of C/EBPb and C/EBPd did not
change. These results indicate that fad104 aﬀects the gene ex-
pression at the mid-phase of adipocyte diﬀerentiation and may
contribute to the signaling pathway at this stage.
It is likely that the inhibition of fad104 expression does not
cause a delay in diﬀerentiation, rather inhibition of diﬀerenti-
ation ability of 3T3-L1 cells. We have checked the diﬀerenti-
ation ability of sifad104 cells and control cells very carefully.
The diﬀerentiation occurred at day 4 in both cells and the
diﬀerentiation reached to a maximum at around 6–8 days.
Throughout this period, the percentage of diﬀerentiated cells in
sifad104 cells is less than that in control cells (data not shown).
However, a further characterization is deﬁnitely needed and
the detailed analyses at a stage of mitotic clonal expansion
should also be elucidated.
Fibronectin is one of the extracellular matrix proteins and
functions as a ligand of integrin. The interaction of integrin
with extracellular ligand leads to the organization of an actin-
containing cytoskeleton and signal transduction [24]. It is also
reported that diﬀerentiation of 3T3-F442A preadipocytes was
inhibited when induced on the ﬁbronectin matrix [25]. This
result indicates the importance of interaction between diﬀer-
entiating cells and the extracellular matrix. It is interesting that
the gene for a ﬁbronectin type III-containing protein, fad104,is transiently expressed during adipocyte diﬀerentiation ac-
companied by major morphological changes. However, the
biochemical function of fad104 remains unknown. Moreover,
it is unclear whether the results obtained here are conserved in
vivo. To elucidate these important points, the development of
knockout mice is now in progress.
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